Keyphrases
Cell-to-cell
100%
Relapsed or Refractory
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Large B-cell Lymphoma
100%
Dual Targeting
100%
CD19
100%
Bicistronic
100%
CD22
100%
Pembrolizumab
80%
Complete Response
60%
Confidence Interval
40%
Remission
20%
Response Rate
20%
Overall Response Rate
20%
Neurotoxicity
20%
Partial Response
20%
T Cell Expansion
20%
Programmed Death-ligand 1 (PD-L1)
20%
Complete Responders
20%
Hospital Days
20%
Durable Remission
20%
Chimeric Antigen Receptor T-cell Therapy
20%
Cytokine Release Syndrome
20%
Stage III-IV
20%
Progression-free
20%
Binder
20%
Antigen Density
20%
Hemophagocytic Lymphohistiocytosis
20%
Antigen Loss
20%
T Cell Exhaustion
20%
Outpatient Administration
20%
Multi-antigen
20%
Immunology and Microbiology
B Cell
100%
Chimeric Antigen Receptor T-Cell
100%
CD19
100%
CD22
100%
Pembrolizumab
80%
Cell Expansion
20%
Progression Free Survival
20%
Hemophagocytic Lymphohistiocytosis
20%
Programmed Death 1 Receptor
20%
Cytokine Release Syndrome
20%
Chimeric Antigen Receptor T-Cell Therapy
20%
T Cell Exhaustion
20%
Medicine and Dentistry
Large-Cell Lymphoma
100%
Chimeric Antigen Receptor T-Cell
100%
Pembrolizumab
80%
Progression Free Survival
20%
Cell Expansion
20%
Outpatient
20%
Neurotoxicity
20%
Programmed Death 1 Receptor
20%
Chimeric Antigen Receptor T-Cell Immunotherapy
20%
Cytokine Release Syndrome
20%
Hemophagocytic Syndrome
20%
Diseases
20%
T Cell Exhaustion
20%
Pharmacology, Toxicology and Pharmaceutical Science
Large Cell Lymphoma
100%
Chimeric Antigen Receptor
100%
Pembrolizumab
66%
Remission
33%
Progression Free Survival
16%
Neurotoxicity
16%
Cytokine Release Syndrome
16%
Hemophagocytic Syndrome
16%
Programmed Death 1 Receptor
16%
Diseases
16%